Sorry if a duplicate: Article in Targeted Oncolog
Post# of 148165
(Total Views: 717)
Posted On: 09/05/2020 11:12:38 PM
Sorry if a duplicate:
Article in Targeted Oncology (Per website: Targeted Therapies in Oncology is dedicated to providing oncology healthcare professionals with leading edge research results and treatment strategies for the use of targeted therapies and immunotherapies to improve outcomes in patients with cancer.)
Leronlimab Moving Toward Breakthrough Designation With Positive mTNBC Data
The FDA has recommended that a preliminary meeting for a potential Breakthrough Therapy designation be requested for leronlimab as a treatment of patients with metastatic triple-negative breast cancer, based on positive data from a phase Ib/II study.
https://www.targetedonc.com/view/leronlimab-m...mtnbc-data
Article in Targeted Oncology (Per website: Targeted Therapies in Oncology is dedicated to providing oncology healthcare professionals with leading edge research results and treatment strategies for the use of targeted therapies and immunotherapies to improve outcomes in patients with cancer.)
Leronlimab Moving Toward Breakthrough Designation With Positive mTNBC Data
The FDA has recommended that a preliminary meeting for a potential Breakthrough Therapy designation be requested for leronlimab as a treatment of patients with metastatic triple-negative breast cancer, based on positive data from a phase Ib/II study.
https://www.targetedonc.com/view/leronlimab-m...mtnbc-data
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼